Literature DB >> 10768108

[The Stennert antiphlogistic-rheologic infusion schema in treatment of cochleovestibular disorders].

O Michel1, T Jahns, M Joost-Enneking, P Neugebauer, M Streppel, E Stennert.   

Abstract

The pathogenetic mechanisms of acute cochleo-vestibular lesions are still unknown, but viral infections and vascular phenomena with impairment of microvascular perfusion are thought to play a major role. Between 1 July, 1986 and 28 February 1998, 1501 patients were treated with an infusion protocol using cortisone, dextrane 40 and pentoxifylline. Group 1 contained 1001 patients with sudden hearing loss, group 2a 107 patients with isolated tinnitus and group 2b 393 patients with labyrinthine disorders (among which were 81 patients with cochleovestibular dysfunction). The records were evaluated retrospectively. In group 1 complete hearing recovery occurred in 44.8%, partially in 40.4%, no change in 12.1% and worsened in 2.6%. In group 2a with isolated tinnitus 17.9% had a complete recovery, 43.9% partial recovery, 35.5% no change and 2.8% worsened symptoms. In group 2b vertigo disappeared in 56.8%, had partial recovery in 21.0% and did not change in 7.4%. In the 1501 patients treated, no significant side-effects were found to the medical interventions used. From these results we conclude that the infusion protocol is safe and effective in the treatment of cochleo-vestibular disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768108     DOI: 10.1007/s001060050030

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  10 in total

1.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

2.  [Intratympanic injection therapy for therapy refractory acute hearing loss: A safe option for secondary treatment].

Authors:  G Mühlmeier; S Maier; M Maier; H Maier
Journal:  HNO       Date:  2015-10       Impact factor: 1.284

3.  Vertigo and tinnitus caused by vascular compression of the vestibulocochlear nerve, not intracanalicular vestibular schwannoma: review and case presentation.

Authors:  Carola J Wuertenberger; Steffen K Rosahl
Journal:  Skull Base       Date:  2009-11

Review 4.  [Pharmacotherapy of acute and chronic hearing loss].

Authors:  G Hesse; A Laubert
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

Review 5.  [Pharmacotherapy in acute tinnitis. The special role of hypoxia and ischemia in the pathogenesis of tinnitis].

Authors:  B Mazurek; H Haupt; J Gross
Journal:  HNO       Date:  2006-01       Impact factor: 1.284

6.  [Rheopheresis for recurrent sudden hearing loss : therapeutic options for patients refractory to infusion therapy].

Authors:  S Uygun-Kiehne; R Straube; A Heibges; R Klingel; H Davids
Journal:  HNO       Date:  2010-05       Impact factor: 1.284

7.  [Psychological distress associated with acute tinnitus].

Authors:  R D'Amelio; C Archonti; S Scholz; P Falkai; P K Plinkert; W Delb
Journal:  HNO       Date:  2004-07       Impact factor: 1.284

8.  Prognostic impact of standard laboratory values on outcome in patients with sudden sensorineural hearing loss.

Authors:  Julia Wittig; Claus Wittekindt; Michael Kiehntopf; Orlando Guntinas-Lichius
Journal:  BMC Ear Nose Throat Disord       Date:  2014-07-09

9.  Disabling vertigo and tinnitus caused by intrameatal compression of the anterior inferior cerebellar artery on the vestibulocochlear nerve: a case report, surgical considerations, and review of the literature.

Authors:  Hamid Borghei-Razavi; Omid Darvish; Uta Schick
Journal:  J Neurol Surg Rep       Date:  2013-12-12

10.  Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro.

Authors:  Esther M Speer; David J Dowling; Jianjin Xu; Lukasz S Ozog; Jaime A Mathew; Avinash Chander; Donglei Yin; Ofer Levy
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.